国家保险机构肿瘤按绩效付费项目与循证抗癌药处方及支出的关联
该观察性差分中的差分研究利用覆盖美国6.7%成年人的行政索赔数据,评估某全国性商业保险公司的肿瘤按绩效付费项目与循证抗癌药处方及支出的关联。结果显示,项目期间循证方案处方率从57.1%升至62.2%,差异为+5.1个百分点(95%CI 3.0至7.2,P<.001),同时抗癌药支出和患者自付支出分别增加3339美元和253美元,但6个月总医疗支出无显著变化。结论认为按绩效付费项目可能有效增加循证抗癌药处方,但未必节省费用。
要点
- 按绩效付费项目与循证抗癌药处方率增加5.1个百分点相关。
- 项目期间抗癌药支出增加3339美元,患者自付增加253美元。
- 6个月总医疗支出无显著变化,提示项目未带来费用节省。
核心结论
- 按绩效付费项目可能有效增加循证抗癌药处方,但可能不会带来费用节省。
研究设计与样本
- 观察性差分中的差分研究,利用覆盖美国6.7%成年人的行政索赔数据,模拟阶梯楔形设计。
- 纳入2013至2017年间由1867名参与肿瘤医生开具抗癌药方案的18岁及以上乳腺癌、结肠癌或肺癌患者。
主要发现
- 循证方案处方率从干预前57.1%升至干预期62.2%,差异+5.1个百分点(95%CI 3.0至7.2,P<.001)。
- 抗癌药支出差异增加3339美元(95%CI 1121至5557,P=.003),患者自付支出差异增加253美元(95%CI 100至406,P=.001)。
- 6个月总医疗支出变化为2772美元(95%CI -181至5725,P=.07),无统计学显著性。
关键数值与推荐
- 主要结局为患者药物方案是否为项目认可的循证方案。
- 暴露为时间变化的二分类变量,患者在接受P4P项目后开具抗癌药方案时取值为1。
临床怎么用
- 肿瘤内科可参考按绩效付费模式推动循证抗癌药处方,但需关注抗癌药支出和患者自付费用可能增加。
- 项目设计时应兼顾费用控制,因总医疗支出未见显著下降。
局限性
- 研究为观察性设计,利用行政索赔数据,可能存在混杂因素。
- 仅纳入乳腺癌、结肠癌和肺癌患者及参与项目的肿瘤医生,外推性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cancer drug prescribing by medical oncologists accounts for the greatest variation in practice and the largest portion of spending on cancer care. We evaluated the association between a national commercial insurer's ongoing pay-for-performance (P4P) program for oncology and changes in the prescribing of evidence-based cancer drugs and spending. METHODS: We conducted an observational difference-in-differences study using administrative claims data covering 6.7% of US adults. We leveraged the geographically staggered, time-varying rollout of the P4P program to simulate a stepped-wedge study design. We included patients age 18 years or older with breast, colon, or lung cancer who were prescribed cancer drug regimens by 1,867 participating oncologists between 2013 and 2017. The exposure was a time-varying dichotomous variable equal to 1 for patients who were prescribed a cancer drug regimen after the P4P program was offered. The primary outcome was whether a patient's drug regimen was a program-endorsed, evidence-based regimen. We also evaluated spending over a 6-month episode period. RESULTS: The P4P program was associated with an increase in evidence-based regimen prescribing from 57.1% of patients in the preintervention period to 62.2% in the intervention period, for a difference of +5.1 percentage point (95% CI, 3.0 percentage points to 7.2 percentage points; P < .001). The P4P program was also associated with a differential $3,339 (95% CI, $1,121 to $5,557; P = .003) increase in cancer drug spending and a differential $253 (95% CI, $100 to $406; P = .001) increase in patient out-of-pocket spending, but no significant changes in total health care spending ($2,772; 95% CI, -$181 to $5,725; P = .07) over the 6-month episode period. CONCLUSION: P4P programs may be effective in increasing evidence-based cancer drug prescribing, but may not yield cost savings.
引用
- Bekelman JE, Gupta A, Fishman E, et al. Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending. J Clin Oncol. 2020. PMID: 33021865. doi:10.1200/JCO.20.00890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。